Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» spinal muscular atrophy
spinal muscular atrophy
New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy
Fierce Pharma
Wed, 05/20/20 - 10:50 am
Novartis
Zolgensma
SMA
spinal muscular atrophy
gene therapy
Europe
Roche shares SMA data ahead of scrap with Biogen, Novartis
Fierce Biotech
Tue, 04/28/20 - 10:59 am
Roche
Biogen
Novartis
SMA
spinal muscular atrophy
risdiplam
clinical trials
With supply tight, Novartis readies gene therapy plant for production
BioPharma Dive
Fri, 02/21/20 - 11:45 pm
Novartis
Zolgensma
spinal muscular atrophy
drug manufacturing
Novartis' latest Zolgensma data bode well for use in older patients
Fierce Pharma
Mon, 10/7/19 - 12:13 pm
Novartis
Zolgensma
SMA
FDA
spinal muscular atrophy
Novartis, shadowed by data scandal, renews case for Zolgensma
Biopharma Dive
Thu, 09/19/19 - 09:56 am
Novartis
Zolgensma
SMA
spinal muscular atrophy
Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial
Fierce Pharma
Wed, 09/18/19 - 11:21 am
Biogen
clinical trials
Spinraza
SMA
spinal muscular atrophy
Novartis
Novartis used manipulated data in winning Zolgensma approval, FDA says
Biopharma Dive
Wed, 08/7/19 - 10:57 am
Novartis
FDA
Zolgensma
data
spinal muscular atrophy
gene therapy
AveXis
Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma
Fierce Biotech
Tue, 05/7/19 - 10:19 am
Roche
PTC Therapeutics
spinal muscular atrophy
risdiplam
Novartis
Zolgensma
Biogen
Spinraza
New Zolgensma data suggest comparable efficacy to Spinraza — analysts
Endpoints
Mon, 05/6/19 - 09:52 pm
Novartis
FDA
spinal muscular atrophy
Zolgensma
AveXis
Biogen
Spinraza
Novartis makes final Zolgensma pitch before FDA decision
BioPharma Dive
Sun, 05/5/19 - 06:51 pm
Novartis
gene therapy
Zolgensma
FDA
spinal muscular atrophy
SMA Moment: Will Gene Therapy Shift Treatment, Costs of Muscle Disease?
Xconomy
Thu, 05/2/19 - 11:00 am
gene therapy
SMA
spinal muscular atrophy
Novartis
Zolgensma
Novartis mulling $1.5 mln-$5 mln price range for SMA gene therapy
Yahoo/Reuters
Wed, 04/24/19 - 12:02 pm
Novartis
Zolgensma
gene therapy
drug pricing
spinal muscular atrophy
Ionis slides after AveXis reports SMA data for Zolgensma
BioCentury
Wed, 04/17/19 - 10:41 pm
Ionis Pharmaceuticals
AveXis
Zolgensma
lcinical trials
spinal muscular atrophy
With FDA decision near, Novartis bolsters SMA gene therapy case
Biopharma Dive
Wed, 04/17/19 - 09:57 am
Novartis
FDA
Zolgensma
spinal muscular atrophy
Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER
Fierce Pharma
Thu, 04/4/19 - 11:54 am
Novartis
ICER
drug pricing
Zolgensma
gene therapy
spinal muscular atrophy
ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy
BioCentury
Sat, 02/23/19 - 04:36 pm
Novartis
Zolgensma
AVXS-101
spinal muscular atrophy
ICER
Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies
Fierce Pharma
Tue, 01/29/19 - 07:21 pm
Novartis
ICER
spinal muscular atrophy
alternative payments
drug pricing
gene therapy
Zolgensma
ICER says gene therapy may be more cost effective for spinal muscular atrophy
Yahoo/Reuters
Thu, 12/20/18 - 11:54 pm
Biogen
Spinraza
Novartis
spinal muscular atrophy
ICER
US benefits manager baulks after Novartis values gene therapy at $4-5 mln
Yahoo/Reuters
Fri, 11/23/18 - 01:12 pm
Novartis
Express Scripts
SMA
spinal muscular atrophy
drug pricing
AVXS-101
Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use
Endpoints
Tue, 11/6/18 - 12:27 am
Novartis
drug pricing
AVXS-101
spinal muscular atrophy
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »